GILD

El interés en corto de Gilead Sciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Gilead Sciences. Los datos de interés en corto se actualizan cada dos semanas.

Gilead Sciences (NASDAQ:GILD) Bolsa, Informe de interés en corto

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Inc

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

<a href="https://www.gov.uk/government/news/seladelpar-approved-to-treat-adult-patients-in-the-uk-with-liver-illness#:~:text=Press%20release-,Seladelpar%20approved%20to%20treat%20adult%20patients%20in%20the%20UK%20with,of%20seladelpar%20under%20close%20review.&amp;text=Seladelpar%20belongs%20to%20a%20group,proliferator%2Dactivated%20receptor%20delta%20agonists.">https://www.gov.uk/government/news/seladelpar-approved-to-treat-adult-patients-in-the-uk-with-liver-illness#:~:text=Press%20release-,Seladelpar%20approved%20to%20treat%20adult%20patients%20in%20the%20UK%20with,of%20seladelpar%20under%20close%20review.&amp;text=Seladelpar%20belongs%20to%20a%20group,proliferator%2Dactivated%20receptor%20delta%20agonists.</a>
&nbsp;
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16 January 2025, approved the medicine seladelpar (Livdelzi) in adults for the treatment of a liver illness called Primary Biliary Cholangitis (PBC), including pruritus. It works by controlling liver problems in the body and making the liver less inflamed&nbsp;
Seladelpar belongs to a group of medicines called peroxisome proliferator-activated receptor delta agonists. The medicine can only be prescribed to adult patients with PBC, including pruritus, in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.&nbsp;&nbsp;
<h4>Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, said:&nbsp;</h4>
"Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us.&nbsp;&nbsp;
"We're assured that the appropriate regulatory standards for the approval of this medicine have been met. As with all products, we will keep its safety under close review."&nbsp;
Seladelpar's recommended dosage is one capsule (10 mg) once daily. The efficacy of seladelpar was primarily demonstrated in patients during a 12-month trial, where the medicine was studied in patients with PBC who had an inadequate response or intolerance to UDCA.&nbsp;
As with any medicine, the MHRA will keep the safety and effectiveness of seladelpar under close review.  Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the MHRA Yellow Card scheme, either through the website (<a href="https://yellowcard.mhra.gov.uk/">https://yellowcard.mhra.gov.uk/</a>) or by searching the Google Play or Apple App stores for MHRA Yellow Card.

Biotech

News

General

"Seladelpar Approved To Treat Adult Patients In The UK With Liver Illness; As With Any Medicine, The MHRA Will Keep The Safety And Effectiveness Of Seladelpar Under Close Review" - UK Gov

-Reuters, citing conference presentation

Health Care

Gilead Exec Says Co Expects To Do "Something Like A Cymabay Acquisition Every Couple Of Years

<ul>
<li>-- Strategic Partnership Strengthens Gilead's Inflammation Research Portfolio with the Addition of LEO Pharma's Preclinical Oral STAT6 Program, Including Targeted Protein Degraders --</li>
<li>-- Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S. --</li>
<li>-- LEO Pharma to Maintain Global Rights to Topical Formulations of the STAT6 Program in Dermatology --</li>
</ul>

Reported Saturday, Gilead And LEO Pharma Join Forces To Accelerate Oral STAT6 Development For Inflammation And Dermatology

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Matthew Harrison upgraded the rating for Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Equal-Weight to Overweight and raised the price target from $87 to $113. Gilead Sciences shares closed at $89.14 on Wednesday. <a href="https://www.benzinga.com/quote/GILD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Jon Tower upgraded McDonald&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) from Neutral to Buy and boosted the price target from $311 to $334. McDonald&#8217;s shares closed at $286.90 on Wednesday. <a href="https://www.benzinga.com/quote/MCD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham analyst Tom Nikic upgraded the rating for Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from Hold to Buy and announced a $475 price target. Lululemon shares closed at $392.92 on Wednesday. <a href="https://www.benzinga.com/quote/LULU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Jay Sole upgraded Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) from Neutral to Buy and raised the price target from $280 to $360. Burlington Stores shares closed at $285.95 on Wednesday. <a href="https://www.benzinga.com/quote/BURL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Anna Andreeva upgraded the rating for NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Neutral to Overweight and raised the price target from $72 to $90. Nike shares closed at $71.29 on Wednesday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Nike stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="549" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10123444/image-59-1024x549.png" alt="" class="wp-image-728650" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10123444/image-59-1024x549.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10123444/image-59-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10123444/image-59-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10123444/image-59.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42917071/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Upgrades

Markets

Analyst Ratings

Trading Ideas

BURL

LULU

This McDonald's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Morgan Stanley analyst Matthew Harrison upgrades Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Equal-Weight to Overweight and raises the price target from $87 to $113.

Price Target

Morgan Stanley Upgrades Gilead Sciences to Overweight, Raises Price Target to $113

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">investor outlook for 2025</a>.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector&#8217;s performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500&#8217;s 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Ahead of the 2025 JPM Healthcare Conference, JP Morgan highlights some investor expectations as sentiment remains mixed for the US Large Cap BioPharma group heading into 2025. The conference is scheduled between 13 January and 16 January.
Obesity is expected to remain a major focus for the industry. The sector&#8217;s focus on the below advancements highlights the growing importance of obesity treatments and related drug innovations:
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): Increased emphasis on incretin therapies as production capacity grows and direct-to-consumer advertising gains traction. Key data catalysts: Phase 3 results for orforglipron, an oral <a href="https://www.benzinga.com/general/biotech/23/07/33339766/ozempic-alternatives-these-two-drugs-show-promise-in-affordability-and-effectiveness-for-weight-l" target="_blank" rel="noreferrer noopener">small molecule GLP-1</a>.</li>
<li>Initial outcomes data for tirzepatide <a href="https://www.benzinga.com/general/biotech/24/08/40460727/eli-lillys-famed-obesitydiabetes-treatment-tirzepatide-shows-potential-to-cut-risk-of-developing-" target="_blank" rel="noreferrer noopener">in type 2 diabetes</a>.</li>
</ul>
Several new product launches are on the radar for 2025. Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) stands out as a top pick, with the anticipated launch of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">Cobenfy for schizophrenia</a>.
JP Morgan analyst Chris Schott expects a strong adoption once broader insurance coverage, expected by the second half of 2025, is in place.
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is also preparing for a mid-2025 launch of lenacapavir for pre-exposure prophylaxis, with promising uptake <a target="_blank" href="https://www.benzinga.com/24/12/42468692/gilead-unveils-new-yearly-hiv-injection-to-offer-hope-for-less-frequent-preventive-dosing" rel="noreferrer noopener">projected into 2026</a>.
Additionally, JP Morgan is monitoring Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Winrevair for pulmonary arterial hypertension, which has already <a target="_blank" href="https://www.benzinga.com/25/01/42768614/uk-approves-mercks-hypertension-drug-acquired-via-11-billion-acceleron-pharma-deal" rel="noreferrer noopener">exceeded early expectations</a>, and Gilead&#8217;s Livdelzi for primary biliary cholangitis, expected to see more significant growth in 2025 <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42016935/gilead-unveils-long-term-data-from-seladelpar-in-patients-with-rare-liver-disease" rel="noreferrer noopener">as access improves</a>.
The analyst is watching for updates on how companies are approaching business development after a relatively quiet 2024. While major changes are not anticipated in the size or type of deals pursued by large-cap companies, JP Morgan expects M&amp;A activity to pick up in 2025.
Large deals over $25 billion remain unlikely, with mid-sized deals around $5-15 billion likely to focus on later-stage, lower-risk assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42898400/sanofis-blood-cancer-drugs-new-subcutaneous-formulation-hits-primary-goal-in-late-stage-in-multiple-myeloma" target="_blank" rel="noreferrer noopener">Sanofi&#8217;s Blood Cancer Drug&#8217;s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma</a></li>
</ul>
Image via Shutterstock

Analyst Color

Large Cap

AMGN

REGN

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference

Galapagos NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPG#NASDAQ">GLPG</a>) has unveiled plans to divide its operations into two entities, aiming to enhance shareholder value and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42866548/galapagos-to-unlock-shareholder-value-by-declaring-its-intent-to-separate-into-two-publicly-traded" rel="noreferrer noopener">sharpen strategic focus</a>.
One entity, referred to as SpinCo, will prioritize developing innovative medicines through transformational transactions, while the core Galapagos company will focus on its global cell therapy leadership in oncology.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40558289/major-investor-says-galapagos-is-undervalued-plans-to-push-on-companys-performance-and-strategic-" rel="noreferrer noopener">Major Investor Says Galapagos Is &#8216;Undervalued,&#8217; Plans To Push On Company&#8217;s &#8216;Performance&#8217; And &#8216;Strategic Opportunities&#8217;</a>
Under the separation plan, SpinCo will have approximately $2.53 billion (2.45 billion euro) of Galapagos&#8217; cash reserves.
It will target oncology, immunology and virology through strategic business deals. SpinCo intends to list its shares on Euronext, with Galapagos shareholders receiving proportional shares of SpinCo. The division will require shareholder approval, with completion anticipated by mid-2025.
As part of the separation, Galapagos will amend its 2019 global Option, License and Collaboration Agreement (OLCA) with Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>).
The updated terms grant Galapagos full global development and commercialization rights to its pipeline, subject to royalties on certain product sales.
After the split, the OLCA will apply exclusively to SpinCo. Gilead will hold a 25% stake in both companies post-separation and maintain representation on SpinCo's board.
Galapagos CEO Paul Stoffels emphasized the separation&#8217;s role in accelerating innovation and growth. He highlighted Galapagos&#8217; renewed focus on its decentralized cell therapy platform, which has shown promise in treating relapsed/refractory non-Hodgkin lymphoma.
To align with this vision, Galapagos plans to exit its small molecule discovery programs and seek partners for related assets, including the TYK2 inhibitor GLPG3667, currently in Phase 2 trials.
The restructuring will result in approximately 300 job reductions across Europe, with significant impacts in Belgium and the closure of its French site.
Galapagos expects to operate from key hubs in the U.S., Netherlands and Belgium, aiming to streamline operations and reduce annual cash burn to 175-225 million euros.
Galapagos anticipates completing the spin-off by mid-2025.
Price Action: GLPG stock is
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42877648/ebay-shares-surge-after-meta-launches-integration-test-for-facebook-marketplace" target="_blank" rel="noreferrer noopener">eBay Stock Surges After Meta Launches Integration Test For Facebook Marketplace</a></li>
</ul>
Photo courtesy of company

GLPG

Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus

CGEN

Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead

Gilead Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>) short percent of float has fallen 6.38% since its last report. The company recently reported that it has 21.98 million shares sold short, which is 1.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.1 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Gilead Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736272822_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Gilead Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Gilead Sciences's peer group average for short interest as a percentage of float is 5.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Gilead Sciences's Recent Short Interest

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 4.41% on an annualized basis producing an average annual return of 12.85%. Currently, Gilead Sciences has a market capitalization of $113.70 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,101.15 today based on a price of $91.23 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736201708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Rep. Marjorie Taylor Greene (R-Ga.) disclosed recent purchases of several stocks on Christmas Eve, according to <a href="https://www.benzinga.com/gov-trades/members/marjorie-taylor-greene">Benzinga Government Trades.</a>
Here's a look at what the far-right politician bought.
What Happened: Greene has been an active trader of stocks while in Congress, based on her disclosures over the years.
After going several years without disclosing any trades, Greene <a href="https://www.benzinga.com/markets/equities/24/05/38611874/marjorie-taylor-greene-reveals-new-stock-trades-after-2-year-gap-berkshire-hathway-goldman-sachs">disclosed several purchases</a> in May. She also made<a href="https://www.benzinga.com/government/24/11/41754747/is-marjorie-taylor-greene-betting-on-trump-victory-buys-apple-meta-tesla-stocks-ahead-of-2024-electi"> multiple transactions</a> later in September, October and November.
Greene recently disclosed multiple stock purchases that happened on Dec. 24. Here are the trades that she made, with each valued between $1,000 and $15,000:
<ul>
<li>Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>)</li>
<li>Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>Applied Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>)</li>
<li>Caterpillar Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>)</li>
<li>Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>)</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</li>
<li>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</li>
<li>Johnson and Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</li>
<li>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>)</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</li>
<li>ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>)</li>
<li>The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)</li>
</ul>
Of these stocks bought in the latest disclosures, Eli Lilly, Gilead and Norfolk Southern are new buys for Greene over the last two years.
The rest of the stocks are already owned by Greene with her adding to her position. Several of the stocks, like Hershey have been bought four times by Greene in 2024.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent123124">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: The trading activity of <a href="https://www.benzinga.com/topic/congress-trading">members of Congress </a>continues to be a hot-button item closely monitored by retail investors and the public.
President Joe Biden <a href="https://www.benzinga.com/24/12/42538504/biden-endorses-ban-of-congressional-stock-trading-nobody-in-the-congress-should-be-able-to-make-money-in-the-stock-market-while-in-office">endorsed a ban</a>, suggesting Congress members shouldn&#8217;t be able to trade stocks and options while in office.
&#8220;Nobody in the Congress should be able to make money in the stock market while they&#8217;re in the Congress,&#8221; Biden said in an interview with political advisor&nbsp;Faiz Shakir.
There have been numerous calls to vote for Congress members to vote for a ban on Congressional trading, but a vote has not happened. Representative&nbsp;Ro Khanna&nbsp;(D-Calif.)&nbsp;<a href="https://www.benzinga.com/general/politics/24/05/39096827/exclusive-khanna-says-shameful-congress-members-profited-from-stocks-calls-for-trading-ban-makin" target="_blank" rel="noreferrer noopener">previously told Benzinga&nbsp;</a>that he will continue to advocate for a vote to ban the practice.
Congressional committee assignments can create conflicts of interest when trades are disclosed. Greene serves on the House Subcommittee on Cybersecurity, Information Technology, and Government Innovation, which could give her information on government contracts for technology companies.
Greene's latest stock purchases in November and the new disclosures show a continued bet on technology stocks going forward. Chip stocks and technology companies were among&nbsp;<a href="https://www.benzinga.com/general/politics/24/10/41584466/these-10-stocks-were-the-best-s-p-500-performers-in-2017-when-trump-was-president-will-history-r" target="_blank" rel="noreferrer noopener">the best performing&nbsp;</a>in the S&amp;P 500 in 2017, Trump&#8217;s first year in the White House previously.
Tech giants Meta and Microsoft remain popular for Greene in 2024 with multiple purchases made. A pending ban of TikTok could benefit Meta in 2025.
Greene is also positioning her portfolio with several healthcare names like Eli Lilly, Gilead and Johnson and Johnson.
A deal between Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) and Hershey could benefit Greene if the chocolate company <a href="https://www.benzinga.com/ma/24/12/42496403/deal-dispatch-hershey-monelez-houlihan-intevac-onion-infowars">approves an acquisition</a>.
While Greene has been actively buying stocks over the last several months, she has not reported selling her shares of Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), the Trump co-founded media company that completed a SPAC merger earlier this year.
Greene <a href="https://www.benzinga.com/government/24/09/41031499/marjorie-taylor-greene-stays-loyal-to-trump-keeps-djt-stock-buys-into-warren-buffetts-berkshire-in-l">disclosed buying</a>&nbsp;Digital World Acquisition&nbsp;shares back in October 2021, the SPAC that took&nbsp;Trump's&nbsp;media company public in March 2024.
The transaction was done with shares trading between $67.96 to $118.80. A tweet from UnusualWhales pins the purchase price at $94.20, meaning Greene is down significantly on her $15,000 to $50,000 purchase in the Trump-linked stock. Shares of DJT trade at $39.13 at the time of writing.
Previous disclosures by Greene have shown buys of Tesla and Berkshire Hathaway stock. Greene's portfolio currently consists of investments tied to some of the richest people in the world including Elon Musk, Warren Buffett, Jeff Bezos, Mark Zuckerberg and Jensen Huang. Her portfolio also has exposure to Trump via his media company.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/01/36459015/10-best-stock-traders-in-congress-in-2023-spoiler-nancy-pelosi-is-back-on-the-list">10 Best Stock Traders In Congress In 2023 (Spoiler: Nancy Pelosi Has Reentered The Chat)</a></li>
</ul>
Image: Shutterstock

Politics

ADBE

AMAT

AMZN

MDLZ

MSFT

NVDA

Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500's 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Mounjaro and Zepbound</a>. The analyst also pointed to the company's robust pipeline and forecasted double-digit revenue and earnings growth into the 2030s.
Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia drug, Cobenfy, which could achieve peak sales of $10 billion.
Similarly, Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) are expected to recover in 2025, following challenges in 2024 related to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare" rel="noreferrer noopener">competitive pressures </a>and regional dynamics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an" rel="noreferrer noopener">affecting key products</a>.
Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is poised for growth with the anticipated mid-2025 launch of lenacapavir <a target="_blank" href="https://www.benzinga.com/quote/GILD" rel="noreferrer noopener">for HIV prevention</a>.
The firm also highlighted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) for its appealing valuation, supported by strong Skyrizi and Rinvoq sales despite fewer near-term <a target="_blank" href="https://www.benzinga.com/quote/ABBV" rel="noreferrer noopener">pipeline developments</a>.
Animal health stocks are also projected to rebound in 2025. JP Morgan views Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) as the strongest pick in the sector, citing its potential for high single-digit revenue <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" rel="noreferrer noopener">growth and margin expansion</a>. IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is another solid choice, though its performance depends on a r<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" rel="noreferrer noopener">ecovery in veterinary visits</a>. Meanwhile, Elanco Animal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) faces uncertainties linked to its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" rel="noreferrer noopener">new product launches</a>.
Specialty pharmaceuticals showed early signs of stabilization in 2024, benefiting from improved pricing stability and supply dynamics. Perrigo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) and Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) are highlighted as promising opportunities, while Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) may face growth challenges despite delivering strong clinical trial <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">results this year</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623487/jp-morgan-defensive-oil-stocks-to-watch-in-2025-amid-70-brent-forecast" target="_blank" rel="noreferrer noopener">Defensive Oil Stocks To Watch In 2025 Amid $70 Brent Forecast: JP Morgan</a></li>
</ul>
Photo via Shutterstock

ABBV

ELAN

IDXX

PRGO

TEVA

VTRS

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

Gilead Sciences Acquires 7.85M Xilio Therapeutics Shares At $1.04 Each, Raising Ownership To Over 10%, Along With 6.1M Pre-Funded Warrants Capped At 19.99% Ownership

Gilead Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>) short percent of float has risen 29.66% since its last report. The company recently reported that it has 23.41 million shares sold short, which is 1.88% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Gilead Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734636613_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Gilead Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Gilead Sciences's peer group average for short interest as a percentage of float is 5.18%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(GILD) - Analyzing Gilead Sciences's Short Interest

—Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026—
—Additional equity investment raises Gilead's ownership stake in Assembly Bio to 29.9%—
–Funding supports pipeline progress, including amendment to accelerate clinical development of Assembly Bio's novel small molecule hepatitis D virus candidate ABI-6250—
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced an equity investment of $20.1 million by Gilead Sciences, Inc. ("Gilead") to purchase additional Assembly Bio common stock and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. With the new equity investment, Gilead increases its equity ownership of Assembly Bio to 29.9%.
Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus (HDV) and hepatitis B virus (HBV). Assembly Bio expects to release data from multiple ongoing clinical studies in the coming year, including the interim Phase 1b proof-of-concept data readout for ABI-5366 projected for the first half of 2025.
The amendment to the collaboration agreement adjusts the option timepoints and option payment structure for ABI-6250, an orally bioavailable viral entry inhibitor for the treatment of HDV, to support updated clinical strategies to accelerate and optimize program development. As part of this amendment, $10 million of option-related payments for this program have been accelerated.

Contracts

ASMB

Assembly Biosciences Announces $30.1M Equity Investment And Accelerated Funding From Gilead To Advance Clinical Development Programs; Additional Equity Investment Raises Gilead's Ownership Stake In Assembly Bio To 29.9%

Gilead Announces FDA Breakthrough Therapy Designation For Trodelvy For Second-Line Treatment Of Extensive-Stage Small Cell Lung Cancer

<ul>
<li>Gilead and Terray Will Leverage Terray's tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest.</li>
<li>Gilead Has Exclusive Option to Develop and Commercialize Products from the Collaboration.</li>
<li>Under the terms of the agreement, Terray will utilize the Terray tNova platform to discover and develop small molecule compounds against a set of targets selected by Gilead.&nbsp;</li>
<li>If Gilead exercises its option to exclusively license the compounds directed to a target, Gilead will be responsible for further development and commercialization activities for products resulting from the collaboration. Terray will receive an upfront payment and is eligible to receive milestone payments associated with the achievement of preclinical, clinical, and sales milestones as well as tiered royalties on net sales of products commercialized by Gilead in connection with the collaboration.</li>
</ul>

Gilead Sciences And Terray Therapeutics Have Entered Into A Strategic Collaboration To Discover And Develop Novel, Small Molecule Therapies Across Multiple Targets

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) has outperformed the market over the past 20 years by 4.26% on an annualized basis producing an average annual return of 12.66%. Currently, Gilead Sciences has a market capitalization of $114.05 billion. 
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a price of $91.51 for GILD at the time of writing.
<h3>Gilead Sciences's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734361210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.
Gilead Sciences Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Biktarvy, Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex, Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Entresto, Exelixis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx, and Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xeljanz are among the five drugs flagged for unsupported price increases.
These five drugs' unsupported net price increases <a target="_blank" href="https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/" rel="noreferrer noopener">produced</a> $815 million in incremental added costs to U.S. payers in 2023. These price increases contributed significantly to the overall spending surge.
ICER's analysis <a target="_blank" href="https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf" rel="noreferrer noopener">revealed</a> that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda, AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Imfinizi and Tagrisso, Bristol Myers Squibb &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo, and Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Prolia
The findings are part of ICER's latest Unsupported Price Increases (UPI) report, which examines the top 10 drugs with significant net price increases in the past year.
ICER's Vice President of Research, Dr. Foluso Agboola, highlighted the impact of these price hikes, noting they exceed inflation rates and strain the healthcare system.
The ICER report highlighted that Gilead's Biktarvy saw its wholesale acquisition cost increase by 5.9%, with its hike costing U.S. payers $359 million in additional drug spending.
According to the ICER report, the Darzalex price before discounts increased by 7.6%, compared to 6.2% for Entresto, 7.5% for Cabometyx, and 6% for Xeljanz.
Those price increases added an additional $190 million, $108 million, $86 million, and $72 million to 2023 U.S. drug spending, respectively.
Methodology Behind ICER's Findings
<ul>
<li>ICER's evaluation followed a detailed protocol introduced in April 2024. The organization assessed drugs meeting criteria such as ranking among the top 250 by U.S. sales revenue and exceeding consumer price index growth plus 2% in their Wholesale Acquisition Cost.</li>
<li>The analysis focused on distinguishing price increases driven by value from those unrelated to new clinical evidence.</li>
<li>Manufacturers provided input, and ICER reviewed published studies for evidence of additional health benefits.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468724/warner-bros-discovery-restructures-with-focus-on-streaming-and-tv-divisions-stock-shoots-up" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Media

EXEL

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

The final European Commission decision is anticipated in the first quarter of 2025. This follows the accelerated approval by the U.S. Food and Drug Administration (FDA) in August 2024.
PBC is a rare, chronic, autoimmune disease of the bile ducts that affects approximately 15 per 100,000 people in Europe, primarily women, and can cause liver damage and possible liver failure if untreated. The most common symptoms of PBC are pruritus (chronic itch) and fatigue, which can be debilitating for some people. The disease currently has no cure and treatment goals for people living with PBC include suppressing liver damage and reducing the symptoms related to cholestasis. The effect of treatment on slowing disease progression is primarily measured by an improvement in liver biochemical tests, including the normalization of alkaline phosphatase (ALP) levels, an important marker of disease progression in PBC.

Gilead Sciences Says Committee For Medicinal Products For Human Use Of European Medicines Agency Recommends Seladelpar For Treatment Of Primary Biliary Cholangitis In Combination With Ursodeoxycholic acid (UDCA) In Adults With Inadequate Response To UDCA Alone, Or As Monotherapy In Those Unable To Tolerate UDCA

Tempering Positive Sentiment Of AI In Biotech

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSM – Research Report), Gilead Sciences (GI...

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Gilead Sciences (GILD) and Abbott Laboratories (ABT)

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $115.00. Mich...

Gilead Sciences: Strategic Growth and Optimism Amidst Market Challenges

The Medicines and Healthcare products Regulatory Agency has approved the medicine seladelpar in adults for the treatment of a liver illness called ...

Seladelpar approved to treat adult patients in the U.K. with liver illness

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing advancements like AI. Therefore, fundamentally sound biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD), which are at the forefront of innovation, could be ideal portfolio additions. Read more... Propelled by rising investments, increasing M&amp;A activities and collaboration, and rapid technological advancements, the biotechnology market is experiencing robust growth and expansion. Further, as the biotech industry evolves, its scope and scale expand to open new opportunities, strongly favoring its prospects.
Considering the industry's bright outlook, it could be wise to invest in innovative biotech stocks Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>), and Gilead Sciences Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>) for potential gains.
Likewise, in 2024, when the biotechnology market witnessed key developments like the approval of CRISPR-based therapy and cell and gene therapy, groundbreaking advancements and avenues will open, the year 2025 will continue to revolutionize the healthcare industry and create sustainable alternatives. Also, the trend of strategic collaboration and M&amp;A among leading biotech companies will continue.
Further, in 2025, investments in cutting-edge <a href="https://www.marketsandmarkets.com/PressReleases/global-biotechnology-outlook.asp">technologies like Artificial Intelligence</a> (AI) will continue to grow. The growth of the biotech industry is also expected to be navigated by increasing developments and activities towards precision medicine. Further, approval and adoption of GLP-1 receptor agonists, like Semaglutide and Tirzepatide, will significantly contribute to the market expansion.
The <a href="https://www.rootsanalysis.com/reports/biotechnology-market.html">global biotechnology market</a> is expected to reach $8.01 trillion by 2035, exhibiting growth at a CAGR of 16% driven by innovation, transformative applications, the development of cutting-edge vaccines and therapies, and the adoption of advanced technologies.
Also, ongoing technological innovations leading to the development of scientific disciplines, like genomics, metabolomics, and proteomics, are helping to address a wide range of issues.
With these encouraging trends in mind, let's delve into the fundamentals of the three top <a href="https://stocknews.com/category/biotech/">Biotech</a> stock picks, beginning with the third choice.
Stock #3: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases globally. The company's products include EYLEA, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
On December 19, REGN announced positive Phase 2 results for two novel monoclonal antibodies, REGN7508 and REGN9933, targeting distinct domains of Factor XI. The antibodies demonstrated strong antithrombotic effects with no clinically relevant bleeding, offering promising anticoagulant options for patients at varying bleeding risks.
During the third quarter that ended September 30, 2024, REGN's total revenue rose 10.6% year-over-year to $3.72 billion. Its income from operations grew 6.2% from the year-ago value to $1.18 billion. The company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> came in at $1.46 billion or $12.46 per share, indicating 10% and 7.5% increases from the prior year's quarter, respectively.
Street expects REGN's revenue and EPS for the first quarter (ending March 2025) to increase 13.3% and 10.1% year-over-year to $3.56 billion and $10.51, respectively. Furthermore, the company has topped the consensus revenue and EPS estimates in three of the trailing four quarters, which is impressive.
Over the past month, REGN's stock has declined 6.4% to close the last trading session at $730.30.
REGN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
REGN has a B grade for Value, Sentiment, and Quality. It is ranked #22 out of 338 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry.
In addition to the POWR Ratings we've stated above, we also have REGN's ratings for Growth, Momentum, and Stability. Get all REGN ratings <a href="https://stocknews.com/stock/REGN/">here</a>.
Stock #2: Biogen Inc. (<a href="https://stocknews.com/stock/BIIB/">BIIB</a>)
BIIB discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases internationally. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS), SPINRAZA, ADUHELM, FUMADERM, BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.
On November 18, BIIB and Samsung Bioepis Co., Ltd. announced that the European Commission (EC) has approved OPUVIZ&#x2122; 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea (aflibercept), developed and registered by Samsung Bioepis. The EC approval reflects a major step for the companies toward expanding access to vital biologic therapies for the needy.
On October 29, BIIB and Neomorph Inc. announced a research collaboration for discovering and developing molecular glue degraders for priority targets in Alzheimer's, rare neurological, and immunological diseases. The multi-target collaboration aims to discover and develop clinical candidates for molecular glue degrader for priority targets.
For the third quarter that ended September 30, 2024, BIIB reported total revenues of $2.47 billion, and the company's income before income tax expense came in at $451 million for the same period. Also, non-GAAP total net income attributable to BIIB and EPS were $595.70 million and $4.08 for the quarter, respectively.
Analysts expect BIIB's revenue and EPS for the fourth quarter (ended December 2024) to grow 1.3% and 16% year-over-year to $2.42 billion and $3.42, respectively. Also, the company topped the consensus EPS estimate in three of the trailing four quarters.
Shares of BIIB have plunged 2.1% over the past month to close the last trading session at $153.15.
BIIB's sound fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.
The stock has an A grade for Value and a B for Growth. Within the Biotech industry, BIIB is ranked #19 of 338 stocks.
<a href="https://stocknews.com/stock/BIIB/">Click here</a> to access additional ratings of BIIB for Quality, Momentum, Sentiment, and Stability.
Stock #1: Gilead Sciences Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is an international biopharmaceutical company engaged in discovering, developing, and commercializing medicines in the areas of unmet medical needs. The company offers products like Biktarvy, Genvoya, Descovy, and Odefsey for treating HIV/AIDS, Veklury for COVID-19, and Epclusa for viral hepatitis.
On December 17, GILD and Terray Therapeutics, Inc. entered into a strategic collaboration aimed at discovering and developing innovative small molecule therapies targeting multiple diseases. The partnership aims to leverage next-generation, AI-driven platforms to shape drug discovery and offer innovative treatments across various therapeutic areas.
On the same date, GILD's Trodelvy&#xAE; (sacituzumab govitecan-hziy) was granted Breakthrough Therapy Designation by the U.S. FDA. Trodelvy&#xAE; is helpful for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.
GILD reported total revenues of $7.55 billion during the third quarter, which ended September 30, 2024. The company's non-GAAP operating income grew 1.1% from the year-ago value to $3.26 billion. Non-GAAP net income attributable to GILD and non-GAAP EPS amounted to $2.53 billion and $2.02 for the quarter, respectively.
In addition, the company's free cash flow increased 155.3% from the prior year's quarter to $4.17 billion.
As per the updated fiscal full-year 2024 guidance, GILD expects a non-GAAP projected operating income of $8 billion - $8.30 billion, and its non-GAAP EPS is expected between $4.25 and $4.45.
Street expects GILD's revenue for the fiscal year (ending December 2025) to increase marginally year-over-year to $28.40 billion, while its EPS for the same year is expected to grow 71.6% year-over-year to $7.56. Moreover, the company has surpassed the consensus revenue estimates in each of the trailing four quarters.
Shares of GILD have surged 34.2% over the past six months and 7.9% over the past year to close the last trading session at $90.63.
GILD's POWR Ratings reflect its bright prospects. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system.
The stock has a B grade for Value, Growth, Sentiment, and Quality. GILD has topped among the 338 stocks in the same industry.
<a href="https://stocknews.com/stock/GILD/">Click here</a> to access additional ratings of GILD for Momentum and Stability.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
GILD shares were trading at $90.14 per share on Wednesday morning, down $0.49 (-0.54%). Year-to-date, GILD has declined -2.41%, versus a 0.38% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/gild-regn-biib-3-biotech-stocks-innovating-the-future-of-medicine/>3 Biotech Stocks Innovating the Future of Medicine</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks Innovating the Future of Medicine

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further… The U.S. biotech sector is experiencing significant growth, fueled by groundbreaking advancements in genetic therapies, personalized medicine, and immunotherapy. As the industry continues to push the boundaries of medical innovation, companies driving breakthroughs in gene therapy and genetic treatments are gaining attention.
Therefore, solid biotech stocks Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>), Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>), and Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>) coulc be ideal buys.
U.S. biotech stocks are primarily driven by advancements in medical research, regulatory approvals, and the ongoing demand for innovative treatments. Breakthroughs in gene therapy, personalized medicine, and immunotherapy are central to investor optimism, as these areas offer potential to address previously untreatable diseases.
Gene therapies are rapidly transforming the landscape of healthcare, offering the potential to cure or significantly improve the treatment of a wide array of diseases. By directly addressing the root causes of genetic disorders through the modification or replacement of defective genes, these therapies provide long-term or even permanent solutions for conditions that were once considered untreatable. The global biotechnology market, which was valued at <a href="https://www.precedenceresearch.com/biotechnology-market">$1.55 trillion in 2024</a>, is projected to reach $4.61 trillion by 2034, at a CAGR of 11.5%.
Considering this growing trajectory, let's discuss further about the <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks:
Stock #3: Vertex Pharmaceuticals Incorporated (<a href="https://stocknews.com/stock/VRTX/">VRTX</a>)
VRTX is a leading biotech company that focuses on treatments for cystic fibrosis and other conditions, including sickle cell disease, diabetes, and cancer, with key products like TRIKAFTA and a diverse clinical pipeline.
In the fiscal third quarter that ended September 30, 2024, VRTX's net product revenues increased 11.6% year-over-year to $ 2.77 billion. Its non-GAAP operating income grew 11.4% from the year-ago value to $1.31 billion. In addition, the non-GAAP net income came in at $ 1.14 billion and $4.38 per share, up 7.5% and 7.4% over the prior-year quarter, respectively.
Street expects VRTX's <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> for the fiscal fourth quarter (ending December 31, 2024) to increase 10.6% year-over-year to $ 2.79 billion. Its EPS for the same quarter is expected to be $4.06. In addition, it surpassed the consensus revenue and EPS estimates in three of the trailing four quarters, which is promising.
The stock plunged down to 4% in the past year to close the last trading session at $402.49.
VRTX's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
VRTX has a B grade in Value. It is ranked #33 out of 336 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech industry</a>.
Beyond what we have stated above, we also have given VRTX grades for Growth, Momentum, Stability, Sentiment, and Quality. Get all the VRTX's ratings <a href="https://stocknews.com/stock/VRTX/">here</a>.
Stock #2: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN develops and commercializes medicines for various diseases, including eye disorders, asthma, cancer, and rare conditions. Key products include EYLEA, Dupixent, and Libtayo, alongside advanced research in gene editing and T cell therapies through collaborations.
On December 19, REGN announced positive Phase 2 results for its monoclonal antibodies REGN7508 and REGN9933, targeting distinct domains of Factor XI. The results demonstrated strong antithrombotic effects with no clinically relevant bleeding, offering promising anticoagulant options for patients at varying bleeding risks.
During the fiscal third quarter that ended September 30, 2024, REGN's revenues increased 10.6% year-over-year to $ 3.72 billion. Its income from operations grew 6.1% from the year-ago value to $ 1.18 billion. In addition, the company's non-GAAP net income and non-GAAP net income per share came in at $ 1.46 billion and $12.46, up 10% and 7.5% over the prior-year quarter, respectively.
Street expects REGN's revenue and EPS for the year ending December 31, 2024, to increase 8.1% and 2.9% year-over-year to $ 14.18 billion and $45.07, respectively. In addition, it surpassed the consensus revenue and EPS estimates in three of the trailing four quarters.
Shares of REGN have gained marginally year-to-date to close the last trading session at $716.26.
REGN's POWR Ratings reflect its robust outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
It has a B grade in Value, Sentiment, and Quality. It is ranked #21 in the same industry.
Click <a href="https://stocknews.com/stock/REGN/">here</a> to see REGN's ratings for Growth, Momentum, and Stability.
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company specializing in treatments for HIV/AIDS, COVID-19, viral hepatitis, oncology, and pulmonary hypertension. Its key products include Biktarvy, Veklury, and Yescarta, and it collaborates with several partners to advance research and innovative therapies.
On December 17, GILD and Terray Therapeutics, Inc. announced a strategic collaboration aimed at discovering and developing innovative small molecule therapies targeting multiple disease areas. This partnership underscores Gilead's commitment to expanding its therapeutic portfolio through cutting-edge scientific alliances.
On November 14, GILD announced the pricing of $3.5 billion in senior unsecured notes, with varying maturities from 2029 to 2064. The offering is expected to close on November 20, 2024, and will support the company's financial strategies and growth initiatives.
It pays an annual dividend of $3.08, which translates to a dividend yield of 3.33% at the prevailing price levels. Its four-year average dividend yield is 4.05%. The company has grown its dividend payment at a CAGR of 4.1% over the past five years.
GILD's total revenues increased 7% year-over-year to $7.55 billion in the fiscal third quarter that ended on September 30, 2024. Its non-GAAP operating income came in at $3.26 billion, up 1.1% year-over-year. Moreover, its non-GAAP net income attributable to Gilead and non-GAAP earnings per share attributable to Gilead stood at $2.53 billion and $2.02, respectively, over the previous quarter.
Street expects GILD's revenue for the fiscal fourth quarter (ending December 31, 2024) to increase marginally year-over-year to $7.16 billion. Its EPS for the same quarter is likely to be $1.72. In addition, it surpassed the consensus revenue estimates in each of the trailing four quarters.
Shares of GILD have gained 8.6% over the past year and 35.1% over the past six months to close the last trading session at $91.23.
GILD's bright prospects are apparent in its POWR Ratings. The stock has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has an A grade for Sentiment and a B for Value, Growth, and Quality. It tops the same industry.
Click <a href="https://stocknews.com/stock/GILD/">here</a> to see GILD's ratings for Momentum and Stability.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
GILD shares fell $0.41 (-0.45%) in premarket trading Tuesday. Year-to-date, GILD has declined -1.23%, versus a 1.58% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Kritika Sarmah</h2> <img src='https:/wp-content/uploads/2022/08/Kritika-Sarmah_Image-3.jpg' style="float:left; padding:5px;width:125px;">Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist. She earned her bachelor's degree in commerce and is currently pursuing the CFA program. With her fundamental approach, she aims to help investors identify untapped investment opportunities.<a href="https://stocknews.com/authors/?author=kritika-sarmah">More...</a>The post <a href=https://stocknews.com/news/gild-vrtx-regn-3-biotech-innovators-advancing-genetic-therapies/>3 Biotech Innovators Advancing Genetic Therapies</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Innovators Advancing Genetic Therapies

Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI +

Welcome to "Sector Spotlight," where The Fly looks at a new industry every week and highlights its happenings. PHARMA SECTOR NEWS:&nbsp;In 2024, dr...

Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations

ABCL

APPTF

BIIB

BIZD

BRKR

CGON

GOOG

GOOGL

HWAIF

ILMN

INSM

ITCI

NMIH

NVSEF

PFLT

PPTDF

RCUS

RHHBY

RHHVF

RLAY

RXRX

SPGYF

SRPT

TCGGY

TCHBF

TECH

TGTX

UPST

VRTX

Press Releases

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH

Longest Follow-Up Data Reported for Kite's Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

Gilead Sciences to Present at Upcoming Investor Conference

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

Comments

Gilead Sciences

Interés en corto

Gilead Sciences (NASDAQ:GILD) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL